- Medicare launched its “Bridge” pilot program today (July 1), covering three weight-loss drugs — Novo Nordisk’s Wegovy injection and pill and Eli Lilly’s Zepbound KwikPen and Foundayo pill — at a $50 monthly copay for eligible members, down from cash prices of up to $450 a month that uninsured seniors have been paying.
- Between 12.5 million and 20 million Medicare members are estimated to be eligible, but experts warn actual uptake will be far lower due to mandatory prior authorization — a process requiring prescribers to request approval based on BMI and other factors before a prescription is filled, which could take days and may prove cumbersome for providers and pharmacies.
- The $50 copay is enabled by deals the Trump administration struck with Eli Lilly and Novo Nordisk in November to sell the drugs to Medicare at $245/month (well below list prices of up to $1,350); Morgan Stanley analysts estimate that even 10% uptake among eligible overweight Medicare members would cost $5.5 billion annually, rising to $11 billion at 20% uptake.
- Coverage is only guaranteed through the end of 2027, and longer-term continuation depends on whether Medicare can persuade private insurers to participate — a prospect insurers have already pushed back on — making Bridge a pilot whose permanence is far from certain.
What Happened?
Medicare’s Bridge program went live today, offering GLP-1 weight-loss drugs to eligible members for the first time at a $50 monthly copay — a watershed moment for the roughly 12.5 to 20 million seniors who may qualify. The drugs covered are Novo Nordisk’s Wegovy (injection and pill) and Eli Lilly’s Zepbound (KwikPen injection and Foundayo pill), both of which have been shown to reduce body weight by 12% to 22% on average over more than a year of treatment. Until now, Medicare has not covered GLP-1s when prescribed for weight loss alone, and drug manufacturers are prohibited from offering direct financial assistance to Medicare patients — leaving seniors to pay cash prices of up to $450 a month. The new $50 copay is funded by a combination of taxpayer dollars and patient contributions, based on the discounted $245/month pricing negotiated with Lilly and Novo Nordisk by the Trump administration in November.
Why It Matters?
GLP-1 drugs have demonstrated benefits beyond weight loss — including reduced cardiovascular risk, lower blood pressure, and potential protection against dementia — making broad Medicare access a public health question with enormous long-term cost implications. But the program also introduces major fiscal uncertainty: the CMS has not released its own enrollment or cost estimates, and independent projections range from $5.5 billion to $11 billion annually depending on uptake. The prior authorization requirement is a deliberate brake on that spending, but it also adds friction for a senior population that may struggle to navigate a complex approval process. CMS Administrator Mehmet Oz said the agency will collect data on enrollment, cost, and patient outcomes to inform longer-term coverage decisions — but acknowledged: “We can’t decide what’s going to happen long-term until we see some of the data.”
What’s Next?
The Bridge program runs through the end of 2027, after which continuation requires private insurers to join — something they have already resisted once, prompting the earlier delay in the program’s rollout. If the pilot data shows favorable outcomes-to-cost ratios, that could build the actuarial case for insurer participation; if enrollment surges beyond projections, cost concerns could dominate. Both Lilly and Novo Nordisk say they are prepared from a supply standpoint after overcoming earlier shortages, and both have formed rapid-response teams to monitor the rollout. The bigger political question: whether Congress will move to make GLP-1 coverage permanent via legislation — a debate that will play out against a backdrop of rising Medicare spending and the “Big Beautiful Bill’s” broader entitlement reforms.
Source: The Wall Street Journal
